JL
Therapeutic Areas
Genprex Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Reqorsa® (quaratusugene ozeplasmid) + Tagrisso® (osimertinib) | Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations post-Tagrisso failure | Phase 1/2 |
| Reqorsa® (quaratusugene ozeplasmid) + Tecentriq® (atezolizumab) | Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1/2 |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 |
| Reqorsa® + other TKIs | Various Cancers | Research |
| GPX-002 | Undisclosed Solid Tumor | Research |
Leadership Team at Genprex
RV
Rodney Varner
Chairman, President & Chief Executive Officer
RC
Ryan Confer
Chief Financial Officer
MB
Mark Berger
Chief Medical Officer
MT
Michael T. Redman
Executive Vice President, Corporate Development & Strategy
JD
J. David Enloe, Jr.
Director
BL
Brent Longnecker
Director